CORRECT: Indivior notes results for painkiller in fentanyl trial Read More
Indivior's painkiller demonstrates positive interaction with fentanyl Read More
EXECUTIVE CHANGES: Dechra Pharmaceuticals picks Alison Platt as chair Read More
LONDON MARKET MIDDAY: Stocks rise as investors eye US inflation data Read More
IN BRIEF: Scopia sells 2.8% stake in Indivior for GBP50 million Read More
LONDON BROKER RATINGS: Upgrades for Lloyds Banking and NatWest Read More
Indivior lifts 2021 revenue guidance amid strong Sublocade sales Read More
LONDON BROKER RATINGS: Citi and JPMorgan differ on Bridgepoint Read More
DIRECTOR DEALINGS: 3i team buy; Scopia trims Indivior stake further Read More
DIRECTOR DEALINGS: IntegraFin COO sells; Chaarat Gold chair buys Read More
DIRECTOR DEALINGS: Scopia slims 16% Indivior stake as chair buys Read More
DIRECTOR DEALINGS: Robert Walters CEO sells GBP2.8 million in shares Read More
IN BRIEF: Indivior to commence USD100 million share repurchase program Read More
IN BRIEF: Indivior unveils profit hike and USD100 million buyback Read More
LONDON MARKET MIDDAY: Investors cheer dividend hikes and buyback plans Read More
UK earnings, trading statements calendar - next 7 days Read More
Indivior agrees new loan facilities of USD250 million maturing in 2026 Read More
LONDON MARKET CLOSE: Lower finish fails to dent FTSE's strong quarter Read More
LONDON MARKET MIDDAY: Stocks slide ahead of US ADP jobs report Read More
Indivior raises profit and revenue guidance after strong start to year Read More
